Iksuda Therapeutics advances IKS014 in Phase 1 trial following positive initial results
Iksuda Therapeutics, a clinical-stage biotechnology firm from the UK specializing in innovative antibody drug conjugates (ADCs) for tumor specificity, reported successful completion of the first ... Read More